抄録
Allogeneic islets are transplanted to many type 1 diabetic patients in the world in recent years. But that situation is limited by the short supply of donner islets, and the recipients must continuously use immunosuppressive agents which may have deleterious effects on the islets. In order to resolve these problems, we can use the bioartificial pancreas (BAP) which can separate xenogeneic or allogeneic cells from the immune system cells of the recipients. So many basic reseach and animal examinations about various types of BAP have being examined to this date. Recently, clinical trials have started on several BAP. The purpose of this review is to show the current status of clinical trials about the BAP.
